HPV-FASTER: broadening the scope for prevention of HPV-related cancer (Q46902171)

26 December 2017

title

HPV-FASTER: broadening the scope for prevention of HPV-related cancer (English)

1 reference

26 December 2017

1 reference

12

1 reference

26 December 2017

Silvia de Sanjosé

18

Silvia de Sanjosé

0 references

Claudia Robles

Claudia Robles

2

0 references

Laia Bruni

Laia Bruni

17

0 references

Mireia Díaz

Mireia Díaz

3

0 references

Xavier Castellsagué

Xavier Castellsagué

16

0 references

Jorge Salmerón

Jorge Salmerón

15

0 references

Joakim Dillner

8

Joakim Dillner

1 reference

PubMed ID

26323382

26 December 2017

Suzanne Marie Garland

14

Suzanne M Garland

1 reference

26 December 2017

Chris J L M Meijer

13

Chris J L M Meijer

1 reference

26 December 2017

Iacopo Baussano

5

Iacopo Baussano

1 reference

26 December 2017

Christine Clavel

6

Christine Clavel

1 reference

26 December 2017

Karl Ulrich Petry

10

Karl-Ulrich Petry

1 reference

26 December 2017

Guglielmo Ronco

7

Guglielmo Ronco

1 reference

26 December 2017

Jack Cuzick

19

Jack Cuzick

1 reference

26 December 2017

Francesc Xavier Bosch José

1

F Xavier Bosch

1 reference

26 December 2017

author name string

Marc Arbyn

4

1 reference

26 December 2017

Matti Lehtinen

9

1 reference

26 December 2017

Mario Poljak

11

1 reference

26 December 2017

language of work or name

English

0 references

publication date

1 September 2015

1 reference

26 December 2017

Nature Reviews Clinical Oncology

published in

1 reference

26 December 2017

volume

13

1 reference

26 December 2017

page(s)

119-132

1 reference

26 December 2017

issue

2

1 reference

26 December 2017

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Global burden of human papillomavirus and related diseases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Anal and perianal squamous carcinomas and high-grade intraepithelial lesions exclusively associated with "low-risk" HPV genotypes 6 and 11.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Chapter 2: The burden of HPV-related cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

The burden and costs of prevention and management of genital disease caused by HPV in women: a population-based registry study in Finland.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Divergent coverage, frequency and costs of organised and opportunistic Pap testing in Finland

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Cervical cancer screening in the United States and the Netherlands: a tale of two countries

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

New technologies and procedures for cervical cancer screening

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Upgrading public health programs for human papillomavirus prevention and control is possible in low- and middle-income countries

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Human papillomavirus testing in primary cervical screening.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-Results from the Hammersmith study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Human papillomavirus and Papanicolaou tests to screen for cervical cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Interlaboratory variation in the performance of liquid-based cytology: insights from the ATHENA trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Cervical cancer screening: on the way to a shift from cytology to full molecular screening

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Guía de cribado del cáncer de cuello de útero en España, 2014

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Chapter 10: New dimensions in cervical cancer screening

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Individual detection of 14 high risk human papilloma virus genotypes by the PapType test for the prediction of high grade cervical lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

HPV screening for cervical cancer in rural India

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Social and psychological impact of HPV testing in cervical screening: a qualitative study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Psychological burden of testing positive for high-risk human papillomavirus on women with atypical cervical cytology: a prospective study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Are women ready for the new cervical screening protocol in England? A systematic review and qualitative synthesis of views about human papillomavirus testing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Lower cost strategies for triage of human papillomavirus DNA-positive women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

The concordance of HPV DNA detection by Hybrid Capture 2 and careHPV on clinician- and self-collected specimens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Reliability of the Xpert HPV assay to detect high-risk human papillomavirus DNA in a colposcopy referral population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

A review of clinical trials of human papillomavirus prophylactic vaccines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Clinical trials of human papillomavirus vaccines and beyond

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Safety of human papillomavirus vaccines: a review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

The Australian experience with the human papillomavirus vaccine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Value of quantitative and qualitative analyses of circulating cell-free DNA as diagnostic tools for hepatocellular carcinoma: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Model-based estimates of long-term persistence of induced HPV antibodies: a flexible subject-specific approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

HPV vaccine against anal HPV infection and anal intraepithelial neoplasia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Modeling cervical cancer prevention in developed countries

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Human papillomavirus vaccine introduction--the first five years

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Organization and quality of HPV vaccination programs in Europe

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

The road ahead for cervical cancer prevention and control

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Age-specific occurrence of HPV16- and HPV18-related cervical cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Cervical screening at age 50-64 years and the risk of cervical cancer at age 65 years and older: population-based case control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

The known unknowns of HPV natural history

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Evidence and impact of human papillomavirus latency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Factors affecting transmission of mucosal human papillomavirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Acceptability of human papillomavirus vaccines among women older than 26 years

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

A cross-sectional survey to assess community attitudes to introduction of Human papillomavirus vaccine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Human papillomavirus vaccine among adult women: disparities in awareness and acceptance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Distinct demographic factors influence the acceptance of vaccination against HPV.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Knowledge and intention to participate in cervical cancer screening after the human papillomavirus vaccine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Recommendations for cervical cancer screening programs in developing countries. The need for equity and technological development.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

New paradigms and challenges in cervical cancer prevention and control in Latin America

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Recommendations for cervical cancer prevention in Central and Eastern Europe and Central Asia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Health and economic implications of HPV vaccination in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Economic evaluation of human papillomavirus vaccination in the United Kingdom

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Age-based programs for vaccination against HPV.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Vaccinating women previously exposed to human papillomavirus: a cost-effectiveness analysis of the bivalent vaccine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Specimen self-collection and HPV DNA screening in a pilot study of 100,242 women.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

The up-to-date evidence on colposcopy practice and treatment of cervical intraepithelial neoplasia: the Cochrane colposcopy & cervical cytopathology collaborative group (C5 group) approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.146

Human papillomavirus vaccines: WHO position paper, October 2014

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26323382

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26323382

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26323382

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2015.146

1 reference

26 December 2017

PubMed ID

26323382

1 reference

26 December 2017